Analytical Data
-
Gene name
CYP3A4
- Application
-
Alternative Names
CYP3A4；CYP3A3；Cytochrome P450 3A4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08684
-
Expression Region
2-503aa
-
AA Sequence
ALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA-
-
Molecular Weight
63.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP3A4 is a member of the cytochrome P450 enzyme family and plays a critical role in the metabolism of a wide variety of drugs and endogenous compounds in the human liver and intestines. As the most abundant P450 enzyme in the human body, CYP3A4 is responsible for the biotransformation of approximately 50% of all pharmaceuticals, including several anticancer medications, antihypertensives, and antiepileptic drugs. Its activity can be significantly influenced by various factors, including genetic polymorphisms, dietary components, and drug-drug interactions, leading to variability in drug efficacy and toxicity among individuals. The recombinant expression of CYP3A4 in heterologous systems, such as bacteria and yeast, has become a vital research tool, allowing scientists to study its enzymatic properties, substrate specificity, and potential inhibitors. The generation of recombinant CYP3A4 enables the exploration of drug metabolism pathways and provides insights into the mechanisms of drug interactions, making it an essential component in drug development and personalized medicine. Understanding the structure-function relationship and regulatory mechanisms of CYP3A4 can pave the way for better therapeutic strategies and safer drug administration, ultimately improving patient outcomes in clinical settings.
